Filtered By:
Specialty: Drugs & Pharmacology
Condition: Thrombosis

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 546 results found since Jan 2013.

Baicalein administered in the subacute phase ameliorates ischemia-reperfusion-induced brain injury by reducing neuroinflammation and neuronal damage
Publication date: September 2019Source: Biomedicine & Pharmacotherapy, Volume 117Author(s): Shilun Yang, Haigang Wang, Yinglin Yang, Rui Wang, Yuehua Wang, Chunfu Wu, Guanhua DuAbstractIschemic stroke is a cerebrovascular disease with high morbidity, high mortality, and high disability, representing a serious threat to human life and health. Clinically, the extensive injury caused by ischemic stroke results from ischemia-reperfusion (I/R) injury thrombolytic treatment. However, there are few reports on the use of medications in the subacute stage of cerebral I/R. Baicalein (5,6,7-trihydroxyflavone) is a biologically active...
Source: Biomedicine and Pharmacotherapy - June 19, 2019 Category: Drugs & Pharmacology Source Type: research

Baicalein administered in the subacute phase ameliorates ischemia-reperfusion-induced brain injury by reducing neuroinflammation and neuronal damage.
Abstract Ischemic stroke is a cerebrovascular disease with high morbidity, high mortality, and high disability, representing a serious threat to human life and health. Clinically, the extensive injury caused by ischemic stroke results from ischemia-reperfusion (I/R) injury thrombolytic treatment. However, there are few reports on the use of medications in the subacute stage of cerebral I/R. Baicalein (5,6,7-trihydroxyflavone) is a biologically active ingredient extracted from the root of Scutellaria baicalensis Georgi. In the present study, we investigated the therapeutic effect of baicalein administered in the su...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - June 18, 2019 Category: Drugs & Pharmacology Authors: Yang S, Wang H, Yang Y, Wang R, Wang Y, Wu C, Du G Tags: Biomed Pharmacother Source Type: research

Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients
Conclusions The presence of comorbidities was linked to NOAC use over vitamin K antagonist, which is different from prescription factor studies in other countries and requires further study.
Source: International Journal of Clinical Pharmacy - September 13, 2019 Category: Drugs & Pharmacology Source Type: research

A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome and percutaneous coronary intervention.
Authors: Gumprecht J, Domek M, Lip GY Abstract Introduction: The non-vitamin K antagonist oral anticoagulants (NOACs) are changing the landscape for stroke prevention in atrial fibrillation (AF) and prevention or treatment of venous thromboembolism (VTE). In patients with AF and concomitant acute coronary syndrome (ACS), the treatment regimen of combined NOACs and P2Y12 inhibitors is gaining popularity. Areas covered: The authors conducted a review of studies published in the last 10 years regarding safety evaluation and effectiveness of apixaban for the treatment of AF and ACS, both alone and in combination with d...
Source: Expert Opinion on Drug Safety - October 4, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Management of Left Ventricular Thrombi with Direct Oral Anticoagulants: Retrospective Comparative Study with Vitamin K Antagonists
ConclusionsThis retrospective observational study found a similar efficacy between DOAC and VKA agents in patients with LV thrombi (70.6% vs. 71.5%); however, when the thrombus remains, VKAs are still the standard of care as it is possible to control INR levels (3 –4) with them.
Source: Clinical Drug Investigation - March 5, 2020 Category: Drugs & Pharmacology Source Type: research

Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations.
CONCLUSION: While the published evidence on use of DOACs in patients at extremes of body weight is sparse, apixaban and rivaroxaban appear to have the most favorable safety and efficacy profiles. Edoxaban and dabigatran should be avoided. PMID: 32426845 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - May 18, 2020 Category: Drugs & Pharmacology Authors: Covert K, Branam DL Tags: Am J Health Syst Pharm Source Type: research

Population Pharmacokinetic/Pharmacodynamic Modeling of Glenzocimab (ACT017) a Glycoprotein VI Inhibitor of Collagen-Induced Platelet Aggregation.
Abstract Glenzocimab (ACT017) is a humanized monoclonal antigen-binding fragment (Fab) directed against the human platelet glycoprotein VI, a key receptor for collagen and fibrin that plays a major role in thrombus growth and stability. Glenzocimab is being developed as an antiplatelet agent to treat the acute phase of ischemic stroke. During a phase I study in healthy volunteers, the population pharmacokinetics (PK) and pharmacodynamics (PD) of glenzocimab were modeled using Monolix software. The PK/PD model thus described glenzocimab plasma concentrations and its effects on ex vivo collagen-induced platelet aggr...
Source: The Journal of Clinical Pharmacology - June 3, 2020 Category: Drugs & Pharmacology Authors: Renaud L, Lebozec K, Voors-Pette C, Dogterom P, Billiald P, Jandrot Perrus M, Pletan Y, Machacek M Tags: J Clin Pharmacol Source Type: research

Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
CONCLUSION: The TA treatment in the European and American populations is more beneficial and safer than CA treatment. However, although the Asian population has this benefit, the risk of bleeding is significantly increased as well, and care should be taken when choosing antiplatelet drugs. PMID: 32534561 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - June 13, 2020 Category: Drugs & Pharmacology Authors: Wu H, Xiang X, Li D, Shen S, Li X Tags: Curr Pharm Des Source Type: research

Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis
ConclusionAcross geriatric subgroups, apixaban was consistently associated with the most favourable benefit-risk profile and should therefore be preferred in geriatric patients with AF. However, research gaps on the impact of increased falling risk, frailty and baseline dementia were identified, requiring careful consideration while awaiting more results.
Source: Frontiers in Pharmacology - September 8, 2020 Category: Drugs & Pharmacology Source Type: research

The harm of anticoagulation in patients with low-risk by CHADS2 and reclassified as high-risk by CHA2DS2VASc: inferences from TRAF cohort.
CONCLUSIONS: Clinical outcomes, net clinical benefit indices are negative; rates of death and hospitalization were significantly higher for OAC in reclassified category. This emphasizes the importance of greater attention to balancing the risks and benefits of OAC in patients with low risk by CHADS2 and reclassified as high-risk by CHA2DS2VASc. PMID: 33215439 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - November 22, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Netosis and Inflammasomes in Large Vessel Occlusion Thrombi
The inflammatory response appears to play a critical role in clotting in which neutrophil extracellular traps (NETs) are the major drivers of thrombosis in acute ischemic stroke (AIS). The inflammasome is an innate immune complex involved in the activation of interleukin (IL)-18 and IL-1β through caspase-1, but whether the inflammasome plays a role in NETosis in AIS remains poorly understood. Here we assessed the levels of inflammasome signaling proteins in NETs and their association with clinical and procedural outcomes of mechanical thrombectomy for AIS. Electron microscopy and immunofluorescence indicate the presence o...
Source: Frontiers in Pharmacology - January 22, 2021 Category: Drugs & Pharmacology Source Type: research

Efficacy and safety of ticagrelor monotherapy in patients undergoing percutaneous coronary intervention: a meta-analysis
Clin Pharmacol Ther. 2021 Mar 5. doi: 10.1002/cpt.2226. Online ahead of print.ABSTRACTDual antiplatelet therapy (DAPT) and subsequent P2Y12 inhibitor monotherapy, particularly ticagrelor, is an emerging treatment strategy in patients undergoing percutaneous coronary intervention (PCI). This meta-analysis was designed to investigate whether short-term DAPT followed by ticagrelor monotherapy is associated with a favorable outcome as compared to standard DAPT. 1-3 months of DAPT was termed "short-term" DAPT, 6-12 months DAPT was termed "standard" DAPT. The primary outcome was the composite of major adverse cardiovascular even...
Source: Clinical Pharmacology and Therapeutics - March 5, 2021 Category: Drugs & Pharmacology Authors: Georg Gelbenegger Christian Schoergenhofer Bernd Jilma Gloria M Gager Al Medina Dizdarevic Mamas A Mamas Biljana Parapid Poonam Velagapudi Jolanta M Siller-Matula Source Type: research

Comparative effectiveness and safety of high ‐dose rivaroxaban and apixaban for atrial fibrillation: A propensity score‐matched cohort study
ConclusionIn this study, composite effectiveness and safety varied between rivaroxaban and apixaban. High ‐dose apixaban was observed to have a better effectiveness and safety.
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - February 27, 2021 Category: Drugs & Pharmacology Authors: Sylvie Perreault, Alice Dragomir, Robert C ôté, Aurélie Lenglet, Brian White‐Guay, Simon Denus, Mireille E. Schnitzer, Marie‐Pierre Dubé, James M. Brophy, Marc Dorais, Jean‐Claude Tardif Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Safety and efficacy of new oral anticoagulants compared to those of warfarin in AF patients with cancer: a meta-analysis of randomized clinical trials and observational studies
ConclusionOur meta-analysis confirms that NOACs are as safe and effective as warfarin and can be applied in the real world; this data can serve as a reference for clinical doctors for formulating treatment strategies.
Source: European Journal of Clinical Pharmacology - April 1, 2021 Category: Drugs & Pharmacology Source Type: research